Conclusion
glycolipid metabolism disorders, PCOS, overweight PCOS, overweight, metabolic disorders
POLYCYSTIC OVARIES, METABOLIC DISORDERS
In summary, both CPA/EE + Met or GLP-1RA + Met improved menstrual cycles and polycystic ovaries. For overweight patients with PCOS, GLP-1RA + Met treatment is more effective than CPA/EE + Met treatment at improving metabolic disorders while also having obvious advantages at increasing ovulation rates among patients. Therefore we recommend that GLP-1RA + Met should be used for patients suffering from severe combined glycolipid metabolism disorders along with high body fat percentages as it can help correct metabolic disorders quickly while also improving menstruation and ovulation. Plasma proteomics analyses shed light on potential molecular mechanisms and suggested several candidate biomarkers, such as PRDX6, FN1, and SERPINB9, for the clinical prevention, diagnosis, or management of overweight PCOS patients. These results present a clinical advance for treating PCOS.